Jump Financial LLC Has $10.02 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Jump Financial LLC cut its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 11.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 63,317 shares of the medical research company's stock after selling 8,567 shares during the quarter. Jump Financial LLC's holdings in Natera were worth $10,023,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Blue Trust Inc. raised its position in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc boosted its stake in shares of Natera by 345.8% in the 4th quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after purchasing an additional 166 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after buying an additional 261 shares during the last quarter. Principal Securities Inc. grew its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in shares of Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after purchasing an additional 332 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insider Activity at Natera

In other news, insider Solomon Moshkevich sold 24,861 shares of the business's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $4,101,319.17. Following the completion of the transaction, the insider now owns 140,684 shares of the company's stock, valued at approximately $23,208,639.48. The trade was a 15.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the transaction, the chief executive officer now directly owns 267,629 shares of the company's stock, valued at $44,150,756.13. This trade represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 325,922 shares of company stock worth $51,603,664. Company insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. Piper Sandler increased their price objective on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. Sanford C. Bernstein raised their price target on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th. Royal Bank of Canada started coverage on Natera in a report on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective on the stock. Morgan Stanley lifted their target price on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Finally, The Goldman Sachs Group upped their price target on Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of "Moderate Buy" and a consensus price target of $175.76.

Natera Stock Down 3.4 %

Natera stock traded down $5.10 during midday trading on Monday, reaching $142.98. The stock had a trading volume of 211,834 shares, compared to its average volume of 1,381,243. Natera, Inc. has a 1-year low of $85.10 and a 1-year high of $183.00. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The firm's fifty day simple moving average is $150.25 and its 200-day simple moving average is $153.01. The stock has a market capitalization of $19.33 billion, a P/E ratio of -81.24 and a beta of 1.80.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. As a group, analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.